Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**W-LHIT** is an investigational traditional Chinese herbal medicine formula for simple obesity. It contains *Ganoderma lucidum*, *Coptis chinensis*, *Astragalus membranaceus*, *Nelumbo nucifera* Gaertn, and *Fructus aurantii*. The formula is intended to support weight loss without appetite suppression and has been associated with changes in gut microbiota, including increased *Akkermansia muciniphila* and *Enterococcus faecium* and decreased Proteobacteria. In a randomized, double-blind, placebo-controlled phase 2 study in 37 adults with simple obesity, oral W-LHIT capsules combined with lifestyle education produced greater mean weight and BMI reductions than placebo over two months; mild gastrointestinal effects were reported and no serious adverse reactions were observed. ([frontiersin.org](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1054674/full))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on W-LHIT.